ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Other studies reported synergy between novel HDACi and imatinib [10, 12, 53], while panobinostat combined with ponatinib showed efficacy against imatinib-sensitive and -resistant CML by targeting BCR-ABL and STAT5 [54].